Stay up to date on the latest in health tech, digital health and health AI news with this weekly brief. This is news from the week of July 13-17.
SpotitEarly partners with HITLAB
Multi-cancer early-detection company SpotitEarly announced a strategic partnership with HITLAB Thursday to accelerate commercialization of its screening test across the U.S.
Through the partnership, HITLAB will support SpotitEarly growth through investor introductions, strategic advisory and speaking opportunities throughout the year.
SpotitEarly plans to bring its breast cancer breath test to commercial markets in 2027, according to a July 16 press release.
SpotitEarly’s non-invasive breath test reads the odor signature of cancer in a person’s breath through its LUCID Bio-AI Hybrid system. The system combines machine learning with the scent-detection abilities of trained canines, using sensors to capture and standardize the dogs’ behavioral and physiological responses into “consistent, data-driven results,” the company says.
“We’ve built the clinical evidence and the partnerships with world-class institutions,” said Shlomi Madar, Ph.D, SpotitEarly CEO, in a statement. “The next step is making sure the investment and healthcare communities see what our data shows and understand the scale of the opportunity. HITLAB sits at the center of digital health innovation and connects us directly with the investors, health-system leaders, and key opinion leaders who can help bring this technology to the patients who need it.”
Novant Health rolls out new primary care model, partners with K Health
Winston-Salem, N.C.-based Novant Health announced Wednesday it has expanded its primary care services with 24/7 patient access through a new, integrated model.
Appointments for Novant Health Virtual Primary Care will be available through the system’s website and MyChart. The redesign is the “first step in a broader effort to transform how and where care is delivered," said Sanjay Gupta, Novant Health executive vice president and chief transformation officer, in a statement.
“While some patients prefer to be seen in-office, many want the convenience of virtual care without sacrificing the trusted, personal relationship that comes with a dedicated primary care clinician,” Gupta said. “By combining our clinical expertise with advanced digital tools, we’re expanding our ability to meet patients where they are, offering high-quality virtual primary care that fits into everyday life while still giving patients the ability to establish ongoing, trusting doctor-patient relationships, just virtual in nature.”
The health system also announced a strategic partnership with AI platform K Health to embed digital AI assistants into virtual care visits. It will also introduce PatientGPT, K Health’s clinical AI tool that is fully integrated into medical records.
GW RhythmX launches RhythmX Pulse on Microsoft Marketplace
GW RhythmX has made its real-time clinical intelligence application, RhythmX Pulse, available on the Microsoft Marketplace, the company announced Wednesday.
The listing enables customers to deploy the solution across Microsoft Azure and other Microsoft platforms.
RhythmX Pulse integrates with Dragon Copilot and converts the captured patient encounters into personalized recommendations for clinicians. The solution checks the documented patient visit against everything else known about the patient, including medical history, current medications, clinical guidelines, social context, payer rules, formulary requirements, and care gaps, according to the company.
Recommendations can include documentation improvements, care-gap alerts, HCC and coding opportunities, guideline-based treatment options and formulary-aware medication alternatives.
Organizations already using Dragon Copilot can add RhythmX Pulse through Microsoft Marketplace, with no separate implementation required.
“Clinical AI is more than summarization or guideline lookups. Now Dragon Copilot users can get the validated and hyper-personalized guidance they need to deliver frontier precision care in every encounter,” said Deepthi Bathina, GW RhythmX CEO and founder, in a statement. “Through Dragon Copilot, GW RhythmX checks that encounter against a patient's full history, the latest guidelines, social and financial intelligence and payer and formulary rules, so clinicians get a clear next best action instead of just a summary or generic guidance.”
GW RhythmX has completed more than 170,000 physician-reviewed clinical validations to date, executives say.
The launch is the first step in a broader collaboration between the companies, GW RhythmX said. Planned future capabilities will extend recommendations earlier and later throughout the care journey.
Machinify adds genetic testing capability
Health intelligence company Machinify announced Monday it is adding genetic testing capabilities to its payment intelligence platform.
Machinify says the expansion represents “another step” towards using its AI to work with sophisticated healthcare payment decisions. Moreover, it expands on Machinify’s previous acquisition of InformedDNA’s genetic testing payment integrity business, executives say.
The company’s platform applies a specialized genetic testing knowledge base with each payer’s medical policies to evaluate claims. In one Medicaid program, according to the company, the capability has identified more than $70 million in savings.
“Specialty areas like genetic testing are more important than ever; the science is evolving daily, and the spend has accelerated dramatically,” said Tom Magnotta, Machinify president of complex payment solutions, in a statement. “We are actively investing in and expanding our content on the platform. Genetic testing is just one of many areas where Machinify is deploying solutions to solve complex challenges for our clients using an AI-first approach.”
The capability is now available to customers through the platform’s pre-payment solution or post-payment extension.